Claudia Gemelli1, Aurora Cuoghi2,3, Stefania Magnani4, Mauro Atti4, Davide Ricci5, Antonio Siniscalchi6, Elena Mancini5, Stefano Faenza6. 1. Science and Technology Park for Medicine, Mirandola, Italyclaudia.gemelli@unimore.it. 2. Science and Technology Park for Medicine, Mirandola, Italy. 3. Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy. 4. Aferetica S.r.l, Bologna, Italy. 5. Nephrology, Dialysis, Hypertension Unit, Teaching Hospital Policlinico S.Orsola-Malpighi, Bologna, Italy. 6. Anaesthesiology and Intensive Care Unit, Teaching Hospital Policlinico S.Orsola-Malpighi, Bologna, Italy.
Abstract
BACKGROUND/AIMS: Many potentially toxic molecules accumulate in the blood during hepatic dysfunction. In clinical practice, it is very difficult to remove bilirubin, the most widely studied toxin, and particularly the unconjugated form, strongly albumin-bound. The aim of this in vitro study was to assess irreversible bilirubin adsorption as a protein-bound compound marker, using Cytosorb® (Cytosorbents Corp.), a new hemoadsorption device designed to remove cytokines. METHODS: We performed 4 in vitro experiments, dynamic and static, with different albumin-bilirubin solutions. RESULTS: All experiments showed the resin's ability to break the albumin-bilirubin complex (Experiment 1, 2), leading to efficient bilirubin removal for 24 h (Removal Rate: 90% Experiment 3) with minimal albumin loss. No sign of bilirubin release from the charged resin was detected (Experiment 4). CONCLUSION: Cytosorb® seems a promising artificial liver support, thanks to its ability to adsorb bilirubin and its proven ability to modulate the cytokines involved in hepatic dysfunction.
BACKGROUND/AIMS: Many potentially toxic molecules accumulate in the blood during hepatic dysfunction. In clinical practice, it is very difficult to remove bilirubin, the most widely studied toxin, and particularly the unconjugated form, strongly albumin-bound. The aim of this in vitro study was to assess irreversible bilirubin adsorption as a protein-bound compound marker, using Cytosorb® (Cytosorbents Corp.), a new hemoadsorption device designed to remove cytokines. METHODS: We performed 4 in vitro experiments, dynamic and static, with different albumin-bilirubin solutions. RESULTS: All experiments showed the resin's ability to break the albumin-bilirubin complex (Experiment 1, 2), leading to efficient bilirubin removal for 24 h (Removal Rate: 90% Experiment 3) with minimal albumin loss. No sign of bilirubin release from the charged resin was detected (Experiment 4). CONCLUSION: Cytosorb® seems a promising artificial liver support, thanks to its ability to adsorb bilirubin and its proven ability to modulate the cytokines involved in hepatic dysfunction.
Authors: Andrea Ascoli Marchetti; Fabio Massimo Oddi; Nicolò Diotallevi; Martina Battistini; Arnaldo Ippoliti Journal: SAGE Open Med Case Rep Date: 2020-12-25
Authors: Thomas Köhler; Mathias W Pletz; Simon Altmann; Carmen Kirchner; Elke Schwier; Dietrich Henzler; Günther Winde; Claas Eickmeyer Journal: Case Rep Crit Care Date: 2021-03-16
Authors: Christina Scharf; Uwe Liebchen; Michael Paal; Andrea Becker-Pennrich; Michael Irlbeck; Michael Zoller; Ines Schroeder Journal: Sci Rep Date: 2021-05-13 Impact factor: 4.379
Authors: Katarzyna Rachunek; Maja Krause; Johannes Tobias Thiel; Jonas Kolbenschlag; Adrien Daigeler; Andreas Bury Journal: Front Surg Date: 2021-12-17
Authors: Thomas Köhler; Elke Schwier; Janina Praxenthaler; Carmen Kirchner; Dietrich Henzler; Claas Eickmeyer Journal: Int J Mol Sci Date: 2021-11-26 Impact factor: 5.923